This study focuses on patients with locally advanced head and neck squamous cell carcinoma, a type of cancer that develops in the tissues of the head and neck region. The study tests two medications: MRG003, a drug that targets a specific protein called EGFR on cancer cells, and pucotenlimab, a medication that helps the immune system fight cancer cells. Both medications are given through intravenous injection, which means they are delivered directly into the bloodstream through a vein.
The purpose of this research is to determine how well patients respond to treatment when receiving MRG003 alone compared to receiving both MRG003 and pucotenlimab together. After receiving these study medications, all patients will proceed to receive chemoradiotherapy, which combines traditional cancer-fighting drugs with radiation treatment.
During the study, patients will receive the study medications over several weeks. MRG003 is given based on body weight, while pucotenlimab is given at a fixed dose. Doctors will monitor patients’ responses to treatment and check for any side effects throughout the study period. The total treatment period may last up to several months, including the initial medication phase and the following chemoradiotherapy.
France 
